The Archer® Reveal ctDNA™ 28 panel for Illumina® is an advanced and user-friendly solution for targeted next-generation sequencing (NGS) of circulating cell-free tumor DNA (ccfDNA/cfDNA/ctDNA) from 28 genes commonly found mutated in solid tumor type cancers.
The Archer® FusionPlex® Comprehensive Thyroid and Lung (CTL) panel is a targeted NGS panel to detect gene fusions, SNV, indels, splicing and gene expression in 36 genes associated with lung and thyroid cancers. This panel complements the Archer® VariantPlex® CTL Panel for comprehensive mutation profiling of fusions, CNVs and variants.
The Archer® Comprehensive Thyroid and Lung (CTL) panel is comprised of two complementary targeted targeted next-generation sequencing (NGS) panels to detect gene fusions, expression, SNVs, CNVs and indels from FFPE, fresh frozen or fine needle aspirate (FNA) samples. CTL is expertly designed to utilize both RNA and DNA in the FusionPlex® and VariantPlex® CTL panels in parallel to cover relevant exons in 45 genes implicated in lung and thyroid cancers.
The Archer® Comprehensive Solid Tumor (CST) panel is comprised of two complementary targeted next-generation sequencing (NGS) panels to detect gene fusions, expression, SNVs, CNVs and indels from FFPE or fresh frozen samples. CST is expertly designed to utilize both RNA and DNA in FusionPlex® and VariantPlex® Solid Tumor panels in parallel to cover relevant exons in 113 genes associated with solid tumors.
The Archer® FusionPlex Solid Tumor panel is a robust targeted sequencing assay to simultaneously detect and identify fusions and other mutations associated with over 50 genes linked to various carcinomas. This panel uses Archer’s proprietary Anchored Multiplex PCR (AMP™)-based enrichment to detect all fusions associated with the genes in a single sequencing assay, even without prior knowledge of fusion partners or breakpoints.
The Archer® VariantPlex Comprehensive Thyroid and Lung (CTL) panel is an next-generation sequencing (NGS)-based targeted sequencing test to detect copy number variations (CNVs), single-nucleotide variants (SNVs) and indels in 31 thyroid and lung cancer-implicated genes. The panel covers entire targeted exons while maintaining high coverage uniformity (> 95%) and on-target reads (99.9%). When used alongside the ribonucleic acid (RNA)-based FusionPlex® CTL panel, fusions, SNVs, CNVs and expression profiles can be analyzed from a single low-input FFPE sample.
The Archer® VariantPlex myeloid panel is a 75-gene targeted sequencing panel for acute myeloid leukemia (AML), myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and some lymphoid malignancy markers. Powered by Anchored Multiplex PCR (AMP™) chemistry, the panel enables deep strand-specific amplification of molecular barcoded deoxyribonucleic acid (DNA) fragments for sequencing.
We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.